BECAFRI - Trademark Details
Status: 606 - Abandoned - No Statement Of Use Filed
Serial Number
87677145
Word Mark
BECAFRI
Status
606 - Abandoned - No Statement Of Use Filed
Status Date
2022-02-14
Filing Date
2017-11-08
Mark Drawing
4000 - Standard character mark
Typeset
Published for Opposition Date
2018-11-13
Attorney Name
Law Office Assigned Location Code
O20
Employee Name
MARINO, JENNIFER ELLEN
Statements
Goods and Services
Pharmaceutical preparations used in connection with anti-aging, namely, for use in the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, and for facial aesthetic surgery, facial aesthetic reconstruction, and breast aesthetic treatment procedures; pharmaceutical preparations for the treatment of migraines; topical antibiotics, anti-inflammatory, anti-infective, anti-glaucoma agents and decongestant formulations; sterile antibiotic ointments; ocular wetting solutions, artificial tears and pharmaceutical preparations for the treatment of minor ocular inflammations and allergic conditions; Pharmaceutical preparations for the treatment of neurological disorders, muscle dystonias, smooth muscle disorders, autonomic nerve disorders, headaches, hyperhydrosis, sports injuries, cerebral palsy, spasms, tremors and pain; dermatological formulations, namely, medicated dry skin lotions and creams, acne medications and medicated skin lightener lotions and creams; Oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing pharmaceutical preparations; Pharmaceutical preparations and medicines for the treatment and prevention of sexual dysfunction; Pharmaceutical preparations and medicines for the treatment of sensory organ disorders; Pharmaceutical preparations and medicines for the treatment of central nervous system disorders; Pharmaceutical preparations and medicines for the treatment of urogenital organ disorders; Pharmaceutical preparations and medicines for the treatment of circulatory system disorders; Pharmaceutical preparations and medicines for the treatment of cardiovascular and blood pressure; Pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations and medicines for the treatment and prevention of irritable bowel syndrome; Pharmaceutical preparations that support, encourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; Antibiotics; Antifungal preparations; Antivirals and Antiprotozoals; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease, dementia, AIDS-related dementia, central nervous system (CNS) disorders, neurological disorders, neurodegenerative disorders, and depression; neuroprotective agent; antidepressants; pharmaceuticals, namely, antipsychotics; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism; Pharmaceutical and cosmeceutical preparations for skin care, namely, medicated skin cleansers, toners, moisturizers, rejuvenators, rehydrating creams, and lotions for the face and body
Classification Information
International Class
005 - Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. - Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes
006, 018, 044, 046, 051, 052
Class Status Code
6 - Active
Class Status Date
2017-11-19
Primary Code
005
Correspondences
Name
Matthew O. Brady
Address
Please log in with your Justia account to see this address.
Trademark Events
Event Date | Event Description |
2017-11-11 | NEW APPLICATION ENTERED IN TRAM |
2017-11-19 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM |
2018-02-20 | ASSIGNED TO EXAMINER |
2018-02-27 | NON-FINAL ACTION WRITTEN |
2018-02-27 | NON-FINAL ACTION E-MAILED |
2018-02-27 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
2018-08-13 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
2018-08-29 | ASSIGNED TO LIE |
2018-08-31 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
2018-08-31 | TEAS/EMAIL CORRESPONDENCE ENTERED |
2018-10-02 | APPROVED FOR PUB - PRINCIPAL REGISTER |
2018-10-05 | LAW OFFICE PUBLICATION REVIEW COMPLETED |
2018-10-24 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
2018-11-13 | PUBLISHED FOR OPPOSITION |
2018-11-13 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
2019-01-08 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
2019-06-07 | TEAS EXTENSION RECEIVED |
2019-06-07 | EXTENSION 1 FILED |
2019-06-07 | EXTENSION 1 GRANTED |
2019-06-11 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
2019-12-20 | TEAS EXTENSION RECEIVED |
2019-12-20 | EXTENSION 2 FILED |
2019-12-20 | EXTENSION 2 GRANTED |
2019-12-24 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
2020-06-12 | TEAS EXTENSION RECEIVED |
2020-06-12 | EXTENSION 3 FILED |
2020-06-12 | EXTENSION 3 GRANTED |
2020-06-16 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
2021-01-04 | TEAS EXTENSION RECEIVED |
2021-01-04 | EXTENSION 4 FILED |
2021-01-04 | EXTENSION 4 GRANTED |
2021-01-06 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
2021-07-06 | TEAS EXTENSION RECEIVED |
2021-07-13 | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
2021-07-06 | EXTENSION 5 FILED |
2021-07-13 | EXTENSION 5 GRANTED |
2021-07-14 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
2022-02-14 | ABANDONMENT - NO USE STATEMENT FILED |
2022-02-14 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED |